Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12616001007426
ACTRN12616001007426
Suspended
未知

Evaluating the Impact of Androgen Deprivation Therapy on Cognition in an Australian Sample of Prostate Cancer Patients

epean and Blue Mountains Local Health District0 sites90 target enrollmentJuly 29, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
epean and Blue Mountains Local Health District
Enrollment
90
Status
Suspended
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 29, 2016
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
epean and Blue Mountains Local Health District

Eligibility Criteria

Inclusion Criteria

  • •\*Gender eligible for study: male
  • •\*Prostate cancer diagnosis
  • •\*MMSE \> 24
  • •\*ECOG status between 0 – 1
  • •\*Speak and read English
  • •\* Planned to commence ADT within 1 month
  • •\* No prior or current ADT

Exclusion Criteria

  • •Participants are not eligible to participate on the following basis:
  • •\*Commenced on ADT
  • •\*Prior ADT
  • •\*Previous or current chemotherapy treatment
  • •\*Previous or current severe psychiatric history as defined by
  • •\- A diagnosed mental illness involving psychosis
  • •\- Hospitalisation for mental health difficulties
  • •\*Current diagnosis of major depressive episode or an anxiety disorder
  • •\*Previous or current neurological difficulties e.g. Seizures or stroke
  • •\*Previous or current significant heart disease e.g. Myocardial infarction, Congestive Cardiac Failure

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigeMetastatic prostate cancerMedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-004853-26-FITurku University Hospital35
Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on prostate specific membrane antigen (PSMA)
EUCTR2017-002345-29-FITurku University Hospital5
Recruiting
Not Applicable
To determine whether androgen deprivation therapy or androgen blockage therapy upregulates receptor activity of Gallium68 Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans for men with castrate resistant prostate cancer.
ACTRN12617001116314St Vincent's Hospital, Sydney20
Active, not recruiting
Not Applicable
Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)Prostate Cancer
NCT03703778Chinese University of Hong Kong300
Recruiting
Not Applicable
Effect of androgen deprivation therapy on uptake of PSMA ligand in patients with salivary duct carcinoma: an explorative study.
NL-OMON48488Radboud Universitair Medisch Centrum14